



Corrigendum

Corrigendum to “Use of the nonavalent HPV vaccine in individuals previously fully or partially vaccinated with bivalent or quadrivalent HPV vaccines” [Vaccine 34 (2016) 757–761]



Pierre Van Damme^{a,*}, Paolo Bonanni^b, F. Xavier Bosch^c, Elmar Joura^d, Susanne Krüger Kjaer^e, Chris J.L.M. Meijer^f, Karl-Ulrich Petry^g, Benoit Soubeyrand^h, Thomas Verstraetenⁱ, Margaret Stanley^j

^a Centre for Evaluation of Vaccination, Vaccine and Infectious Diseases Institute, University of Antwerp, Antwerp, Belgium

^b Department of Health Sciences, University of Florence, Florence, Italy

^c Cancer Research Epidemiology Program, Catalan Institute of Oncology, IDIBELL, Barcelona, Spain

^d Department of Obstetrics and Gynecology, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria

^e Department of Gynaecology, Juliane Marie Centre, Rigshospitalet, Copenhagen University Hospital and the University of Copenhagen, Copenhagen, Denmark

^f Department of Pathology, Free University Medical Center, Amsterdam, The Netherlands

^g Department of Gynaecology and Obstetrics, Klinikum Wolfsburg, Wolfsburg, Germany

^h Sanofi Pasteur MSD, Department of Medical Affairs, Lyon, France

ⁱ P95, Epidemiology and Pharmacovigilance Consulting and Services, Leuven, Belgium

^j Department of Pathology, Cambridge University, Cambridge, UK

The authors regret that an error occurred in [Table 1](#) and the text “no evidence” should be replaced by “incomplete”. The corrected version of [Table 1](#) is reproduced below.

The authors would like to apologise for any inconvenience caused.

DOI of original article: <http://dx.doi.org/10.1016/j.vaccine.2015.12.063>

* Corresponding author. Tel.: +32 32652538; fax: +32 32652640.

E-mail address: pierre.vandamme@uantwerp.be (P. Van Damme).

<http://dx.doi.org/10.1016/j.vaccine.2016.07.035>

0264-410X/© 2016 The Author(s). Published by Elsevier Ltd.

This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Table 1
Scenarios and proposed approaches, for girls 9–14 years of age.

Scenario	Month 0	Month 2	Month 6	Month 12	Month 18	Expected protection*
Sequential doses administration						
A	2vHPV		2vHPV			2 types
	2vHPV		2vHPV	9vHPV	9vHPV	2 types and likely protection for the 7 extra types
	4vHPV		4vHPV			4 types
	4vHPV		4vHPV	9vHPV	9vHPV	4 types and likely protection for the 5 extra types
B	2vHPV	2vHPV				Incomplete
	2vHPV	2vHPV	9vHPV			2 types
	2vHPV	2vHPV	9vHPV	9vHPV		2 types and likely protection for the 7 extra types
	4vHPV	4vHPV				Incomplete
	4vHPV	4vHPV	9vHPV			4 types
	4vHPV	4vHPV	9vHPV	9vHPV		4 types and likely protection for the 5 extra types
C	2vHPV					Incomplete
	2vHPV		9vHPV			2 types
	2vHPV		9vHPV	9vHPV		2 types and likely protection for the 7 extra types
	4vHPV					Incomplete
	4vHPV		9vHPV			4 types
	4vHPV		9vHPV	9vHPV		4 types and likely protection for the 5 extra types
Revaccination						
D	2vHPV	2vHPV	2vHPV			2 types
	2vHPV	2vHPV	2vHPV	9vHPV	9vHPV	2 types and likely protection for the 7 extra types
	4vHPV	4vHPV	4vHPV			4 types
	4vHPV	4vHPV	4vHPV	9vHPV	9vHPV	4 types and likely protection for the 5 extra types

 : already received  : additional

*: expected according to currently available data and expert judgment, the role of cross-protection provided by the bi- and quadrivalent was ignored.